Highlights Alaunos Therapeutics, Inc.

Equities

TCRT

US98973P2002

Market Closed - Nasdaq Other stock markets 16:30:00 2024-05-08 EDT			5-day change	1st Jan Change
1.32 ^USD	+1.54%		+2.33%	+24.47%

04-01	Alaunos Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
03-05	North American Morning Briefing : S&P 500 Futures -2-	DJ

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Alaunos Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	04-01	CI
North American Morning Briefing : S&P 500 Futures -2-	03-05	DJ
Reverse Split: 1 of 15	01-31	FA
Alaunos Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-14	CI
Alaunos Therapeutics, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2023	23-08-14	CI
Alaunos Therapeutics Announces Presentation At the 2Nd Hawaii Global Summit on Thoracic Malignancies	23-06-29	CI
Alaunos Therapeutics to Present Early Data from TCR-T Library Phase 1/2 Trial at 2023 American Society of Clinical Oncology Annual Meeting	23-05-25	CI
Alaunos Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-10	CI
Precigen, Inc. Announces Amendment of Its Exclusive License Agreement with Alaunos Therapeutics, Inc	23-04-03	CI
Alaunos Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-07	CI
Alaunos Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	23-03-07	CI
Alaunos Therapeutics, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2022	22-11-14	CI
Alaunos Therapeutics, Inc. Highlights Data from TCR-T Library Phase 1/2 Trial at the CRI-ENCI-AACR Sixth International Cancer Immunotherapy Conference	22-09-21	CI
Alaunos Therapeutics Announces Early Clinical Data Showing Objective Clinical Response Using Its TCR-T Cell Therapy	22-09-06	CI
Alaunos Therapeutics to Present at the CRI-ENCI-AACR Sixth International Cancer Immunotherapy Conference	22-08-24	CI
Alaunos Therapeutics Q2 Loss Narrows -- Shares Rise	22-08-15	MT
Alaunos Therapeutics, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2022	22-08-15	CI
Alaunos Therapeutics, Inc. and National Cancer Institute Extend Cooperative Research and Development Agreement for Development of Personalized TCR-T Cell Therapies to 2025	22-06-27	CI
Alaunos Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-16	CI
Alaunos Therapeutics, Inc. Doses First Patient in TCR-T Library Phase 1/2 trial for the Treatment of Patients with Solid Tumors	22-05-02	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Alaunos Therapeutics, Inc.

Equities

TCRT

US98973P2002

Highlights

Filters